Published in The Lancet · View the paper (DOI)
A phase 3 trial found that deramiocel, a heart-derived cellular therapy, slowed muscle weakening and preserved heart function in boys and young men with advanced Duchenne muscular dystrophy. The therapy also showed promise in reducing scarring in the heart.
Coverage from 2 institutions